Cardiovascular Research

Cardiovascular Research 2000 48(2):194-210; doi:10.1016/S0008-6363(00)00184-X
© 2000 by European Society of Cardiology

This Article Abstract FREE Full Text (PDF) E-letters: Submit a response Alert me when this article is cited Alert me when E-letters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (51) Request Permissions Disclaimer Google Scholar Articles by McLean, P. G. Articles by Ahluwalia, A. Search for Related Content PubMed Articles by McLean, P. G. Articles by Ahluwalia, A. Social Bookmarking          What's this?

Copyright © 2000, European Society of Cardiology

Kinin B₁ receptors and the cardiovascular system: regulation of expression and function

Peter G. McLean^a,b,*, Mauro Perretti^b and Amrita Ahluwalia^a

^aCenter for Clinical Pharmacology, Department of Medicine, The Rayne Institute, University College London, 5 University Street, London WC1E6JJ, UK
^bDepartment of Biochemical Pharmacology, The William Harvey Research Institute, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1M6BQ, UK

^* Corresponding author. Tel.: +44-207-679-6619; fax: +44-207-691-2838 p.mclean{at}ucl.ac.uk

Received 24 March 2000; accepted 7 July 2000

	Abstract

Top Abstract 1 Introduction 2 The kinin B1... 3 B1 receptor regulation:... 4 Synthesis of B1... 5 Kinin B1 receptor... 6 Role played by... 7 Conclusions References

 
Kinins are important peptide mediators of a diverse range of physiological and pathological functions of the cardiovascular system. The kinin peptides exert their effects by selective activation of two distinct G-protein coupled receptors termed B₁ and B₂. The principal kinin peptides involved in the acute regulation of cardiovascular function during normal physiology are bradykinin (BK) and Lys-BK which produce their effects via activation of B₂ receptors. The B₁ receptor is activated by the des-Arg⁹kinin metabolites namely des-Arg⁹BK and Lys-des-Arg⁹BK, the synthesis of which are increased during inflammation. The B₁ receptor, which is not constitutively expressed, is induced in various pathologies relating to inflammation. Recent investigations into the molecular mechanisms of B₁ receptor induction and their distribution and function in the cardiovascular system have shown that following an inflammatory stimulus the B₁ receptor is induced and may play an important role in modulation of cardiovascular function. This review summarises recent studies on B₁ receptor expression and function in the cardiovascular system and discusses the role of these receptors in regulation of circulatory homeostasis and their potential as therapeutic targets.

KEYWORDS G-proteins; Infection/inflammation; Receptors; Signal transduction

	1 Introduction

Top Abstract 1 Introduction 2 The kinin B1... 3 B1 receptor regulation:... 4 Synthesis of B1... 5 Kinin B1 receptor... 6 Role played by... 7 Conclusions References

 
The kinin peptides, particularly bradykinin (BK), Lys-BK (kallidin) and their biologically active des-Arg⁹ metabolites are the functional components of the kallikrein–kinin system. Kinins are important mediators of a diverse range of physiological and pathological responses of the cardiovascular system. The physiological actions of this system are produced by two endogenous kinins, BK and Lys-BK, formed by proteolytic cleavage of high- and low-molecular-weight kininogens (HMWK and LMWK) by plasma or tissue kallikrein (PK or TK), respectively. BK and Lys-BK are metabolised and deactivated by kininase I or kininase II (also known as angiotensin converting enzyme). The activity of kininase I is of particular relevance to this review in that it produces kinin metabolites without the C-terminal arginine residue, des-Arg⁹BK (DABK) and Lys-des-Arg⁹BK (Lys-DABK) from BK and Lys-BK, respectively. Whilst these des-Arg⁹ metabolites are largely inactive in normal conditions, in certain immuno-pathological situations they produce responses characteristic of inflammation including vasodilation, oedema and leukocyte recruitment within the microcirculation.

The kinins mediate their effects via the selective activation of kinin receptors of which there are two types, B₁ and B₂. The B₂ receptor is constitutively expressed and mediates the majority of the acute vascular actions of BK [1]. In contrast, the B₁ receptor is generally absent from normal tissue but following an inflammatory insult, receptor expression is induced in a variety of cell types including vascular smooth muscle cells (VSMC), endothelial cells (EC) and fibroblasts (see below). The activity of the kinins suggests that they may be involved in inflammatory cardiovascular disease, and the inducibility of the kinin B₁ receptor makes it an exciting potential therapeutic target in such pathological conditions. This review will address the role of B₁ receptors in the physiology and pathophysiology of the cardiovascular system and will highlight the therapeutic potential of agents that interact with this system.

	2 The kinin B1 receptor: an inducible G-protein-coupled receptor (GPCR)

Top Abstract 1 Introduction 2 The kinin B1... 3 B1 receptor regulation:... 4 Synthesis of B1... 5 Kinin B1 receptor... 6 Role played by... 7 Conclusions References

 
The B₁ receptor was first defined as mediating the contractile effect of kinins in the rabbit isolated aorta [2]. Regoli and Barabé [3] later suggested the existence of two types of kinin receptor in 1980 based on differential in vitro tissue reactivity to the endogenous agonists DABK and BK. The order of agonist potency at B₁ receptors was shown to be DABKTyr(Me)⁸ BK, with a reverse order at the B₂ receptor (i.e. BK<Tyr(Me)⁸BK<DABK) [3]. This profile is determined by the discriminating nature of the C-terminal arginine of B₂ receptor selective agents, that is absent in B₁ receptor selective compounds. The selectivity of the kinin peptides is further determined at the receptor by differences in a single position in the third transmembrane domain of the human B₁ and B₂ receptors [4]. The reader is referred to recent excellent reviews discussing kinin receptor ligands in greater detail [5,6]

In 1992, Phillips et al. [7] demonstrated the expression of both B₁ and B₂ receptors in Xenopus oocytes injected with mRNA from NG108-15, rat uterus, and human fibroblast cell line WI38. Structural analysis revealed that the receptors are encoded by distinct mRNA [8]. The human B₁ receptor gene was subsequently cloned from human embryonic lung fibroblasts [9] and was shown to be a member of the 7-transmembrane domain GPCR family. The mouse [10], rat [11] and rabbit [12] B₁ receptors display functional and structural homology with the human receptor. The rabbit receptor shows greatest homology with the human receptor whilst homology with the rodent receptors is relatively low. Interestingly this difference in homology is demonstrated by differences in preferred agonists; Lys-DABK in humans and rabbits and DABK in rodents [5]. This selectivity of Lys-DABK for the human B₁ receptor depends on interaction between the peptide N-terminal L-lysine and the fourth extracellular domain of the human B₁ receptor [13].

	3 B1 receptor regulation: mechanisms of induction

Top Abstract 1 Introduction 2 The kinin B1... 3 B1 receptor regulation:... 4 Synthesis of B1... 5 Kinin B1 receptor... 6 Role played by... 7 Conclusions References

 
The low homology (36%) between the B₁ and B₂ receptors suggests that both receptors may be components of very different regulatory systems [14]. One important example of this is the differential regulation of their expression. The inducibility of the B₁ receptor was first reported by Regoli et al., [2] who described a time- and protein synthesis-dependent appearance of contractile reactivity to DABK in rabbit isolated aorta following 2–3 h of tissue incubation in physiological buffer [15]. This is due to de novo synthesis of B₁ receptor since the response is absent in tissues treated with inhibitors of RNA transcription, translation or of protein maturation [5].

The stimulus for post-isolation B₁ receptor induction in these in vitro studies is unclear but may be related to the trauma of isolating vessels ex vivo. B₁ receptor upregulation occurs, in vitro and in vivo, under the control of specific cytokines released in situations of trauma and stress, including interleukin (IL)-1β and tumour necrosis factor (TNF)- [16–18]. Additionally, studies in vitro show that certain cytokines and growth factors (e.g. IL-1β, IL-2, interferon-, epidermal growth factor and oncostatin) increase the rate at which a B₁ receptor-mediated response develops as a consequence of tissue isolation and incubation [15,17–21]. This upregulation is again due to de novo protein synthesis and is sensitive to glucocorticoids [17,22]. Of all the cytokines IL-1β has been shown to be the optimal inducer of B₁ receptor expression in various cell types of several species in vitro [18,23] including human embryo lung fibroblasts. In these cells IL-1β upregulates B₁ receptor mRNA expression at both a transcriptional and post-transcriptional level [24,25]. In addition, agents that stimulate the synthesis of these cytokines, in particular bacterial lipopolysaccharide (LPS) also lead to functional B₁ receptor expression when administered either in vitro or in vivo [16,18,26]. B₁ receptor induction also occurs following heat stress, another immunopathological stimulus [27].

The induction of functional B₁ receptor-mediated responses is associated with B₁ receptor mRNA and protein expression. This was first shown in the rat isolated heart where in vitro perfusion with IL-1β promoted B₁ receptor induction at both the molecular (mRNA expression) and functional level (coronary vasodilation) [18]. This inducibility to IL-1β has also been demonstrated in vivo for the first time in our laboratory [28] (see below).

Studies attempting to identify the molecular mechanisms involved in B₁ receptor induction implicate the inflammatory transcription factor, nuclear factor B (NF-B). Interestingly NF-B is not only involved in mediating certain B₁ receptor effects but also receptor induction [24,29,30]. Accordingly, NF-B binding domains [24,29] have been identified in the promoter region of the B₁ receptor gene and IL-1β and TNF-induced B₁ receptor expression is directly related to NF-B activation [5]. Additionally, it has been proposed that B₂ receptor activation and consequent desensitisation may be a direct stimulus for B₁ receptor induction since B₂ receptor agonists also cause NF-B activation [31,32].

Apart from differential expression profiles, kinin receptors also display important differences in their susceptibility to desensitisation. When activated by an agonist, B₂ receptors undergo desensitisation and internalisation [33–35] a characteristic accounting for the rapid reversibility of its biological effects in vitro. Conversely, B₁ receptors, once induced, are not internalised or desensitised [20,33–35]. This difference may be explained by the presence of a large C-terminal loop in the B₂ receptor containing Ser and Tyr residues, typical phosphorylation sites [36,37]. In addition, Cys324 in the cytoplasmic carboxyl terminus of the B₂ receptor appears to play an integral role in agonist-induced internalisation. Replacement of the cytoplasmic carboxyl terminus of the B₂ receptor starting from Cys324, with that of the B₁ receptor (beginning at Cys330) greatly reduced ligand internalisation without significantly altering ligand binding affinity or coupling efficiency. In contrast, the corresponding replacement in the B₁ receptor led to an increase of ligand internalisation without altering affinity or coupling. These results indicate that the cytoplasmic carboxyl terminus of the human B₂ receptor contains sequences that are necessary and sufficient to permit rapid ligand-induced sequestration of human kinin receptors and internalisation of their agonists [34]. This differential susceptibility to desensitisation would support the hypothesis that an integrated system develops from B₂ receptor-mediated acute inflammation to a sustained B₁ receptor-mediated chronic, or at least prolonged, inflammatory response. Thus one could speculate that B₂ receptors are unlikely to be involved in sub-acute and chronic inflammatory conditions, whereas B₁ receptors are better equipped to mediate the development and progression of a chronic inflammatory response.

	4 Synthesis of B1 receptor endogenous ligands: the kallikrein–kinin system

Top Abstract 1 Introduction 2 The kinin B1... 3 B1 receptor regulation:... 4 Synthesis of B1... 5 Kinin B1 receptor... 6 Role played by... 7 Conclusions References

 
The synthesis of kinins is determined by the activity of the kallikrein–kinin system that is comprised of two separate pathways differentiated by their location: the plasma and tissue systems [5]. The various elements of the kallikrein–kinin system have been reviewed in detail elsewhere (see Bhoola et al. [1]; Kaplan et al. [38]). In brief, the substrates for kinin synthesis are the multi-domain proteins known as kininogens of which there are three types; high molecular weight kininogen (HMWK), low molecular weight kininogen (LMWK) and T-kininogen. The kininogens contain the nine amino acid peptide sequence for BK (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg). HMWK, the precursor of BK, is a circulating protein in the plasma system, whereas LMWK, the precursor for Lys-BK, is distributed in tissues, fibroblasts and other structural cells within connective tissue [1]. T-kininogen is the rodent equivalent of human HMWK [1]. The human kininogen gene has been mapped to chromosome 3 (3q26-3qter) [39] that codes, via alternative splicing, for the expression of both HMWK and LMWK.

Kallikreins are the enzymes that cleave kininogens and liberate kinins. Plasma kallikrein (PK) releases BK from HMWK [40]; a process that is upregulated during an inflammatory insult such as ischaemia–reperfusion (I/R) injury [41]. There is also evidence that HMWK adsorbed on extracellular proteins of Streptococcus pyrogenes, an important pathogen in ‘sepsis’ can release BK in the presence of prekallikrein [42] thus implicating kinin generation in the pathophysiology of this disease. Tissue kallikreins (TK) are a family of serine proteases closely related to PK and are highly effective in the generation of biologically active kinins. Human TK preferentially releases the decapeptide Lys-BK from kininogens, as found in the nasal secretions of subjects with allergic or viral rhinitis [43]. Human TK is widely expressed in many tissue types including glandular and duct cells, as well as in neutrophils [44], cultured VSMCs, colonic goblet cells, and renal distal tubules and collecting ducts [45–48].

4.1 Kinin metabolism
The kinins are metabolised by several different enzymes, but the two most relevant with regard to the deactivation of BK are kininase I and kininase II. BK exhibits a very short half-life (10–50 s) in blood plasma in vitro and in vivo [49]. Kininase II, otherwise known as angiotensin I converting enzyme (ACE), is the most efficient and the major mechanism for BK inactivation [50], removing the C-terminal dipeptide from BK or Lys-BK and generating biologically inactive fragments. Assays for BK-like peptides have shown that kininase II accounts for between 40 and 75% of the hydrolysis of exogenous synthetic BK by serum or cardiac membrane preparations of humans, rabbits or rats [49,51]. Kininase II is predominantly located on the surface of the luminal membrane of ECs and is therefore in a prime location for the inactivation of circulating BK.

Other peptidases including aminopeptidase P and neutral endopeptidase (NEP) also play an important role in kinin metabolism in vivo. Aminopeptidase P is responsible for up to 30% of total BK metabolism in rat lung and coronary circulation [52,53]. NEP, also a membrane-bound peptidase, located in high concentration on leukocyte membranes [50,54] cleaves two bonds in BK [55] and is responsible for 10–20% of BK inactivation [1]. The NEP homologue endothelin converting enzyme, located at the surface of EC and SMCs can also metabolise BK as efficiently as it metabolises big endothelin [56,57].

Kininase I enzymes (otherwise known as Arg carboxypeptidases) play a lesser role in the deactivation of BK being responsible for less than 10% of total BK metabolism [49]. However, kininase I activity is of particular importance, since this enzyme is responsible for the generation of the des-Arg⁹kinins. Under normal conditions B₁ receptors are absent and these fragments remain functionally ‘silent’ and it is only following situations where these receptors have been induced (see above) that des-Arg⁹ metabolites show activity. Kininase I is composed of the arginine carboxypeptidases, carboxypeptidase N in the plasma and carboxypeptidase M in tissues (predominantly membrane-bound and widely distributed, including in the microvasculature [50,54]). The half-life of DABK is 4- to 12-fold higher than that of BK under comparable experimental conditions [49,51] and this may explain why the in vivo concentration of DABK is consistently higher than that of BK. Therefore, it appears that, whilst the synthesis of DABK is not considerable its half life endows it with a much greater capacity to accumulate than BK. Interestingly, blocking the competing kininase II pathway with enalaprilat improves the conversion of BK to DABK [49,51]. The techniques used to determine the above kinetics are limited by the fact that they only measured kinin metabolism in normal, non-inflammatory tissue/cells. It is possible that the formation of des-Arg⁹kinins is greater at inflammatory sites than in plasma or normal tissue (see below).

4.2 Kallikrein–kinin system during injury and inflammation
All the necessary components required for kinin synthesis are not only present but elevated at sites of inflammation. In models of sepsis and myocardial I/R injury, the levels of detectable des-Arg⁹kinins are increased 2 to 4-fold [41,58]. This elevation may be due to several factors including the possibility that plasma protein extravasation, at sites of inflammation, will provide substrate (HMWK) and enzyme (PK) for enhanced BK synthesis [59]. Additionally, during an inflammatory response the activity of the kallikrein–kinin system is enhanced by activation of the tissue kallikrein–kinin pathway [14]. Firstly, levels of LMWK are elevated by inflammatory cytokines [60]. Secondly, not only is TK present in and secreted from infiltrating leukocytes [5,44] but the synthesis of this protease is enhanced after trauma or inflammation [61]. Other enzymes that may also catalyse kinin formation are neutrophil elastase and mast cell tryptase, also present at sites of inflammation [62]. Additionally, in experimental models of sepsis, there is evidence demonstrating that elevated levels of endogenous B₁ receptor ligands (i.e. des-Arg⁹kinins) are associated with increased expression of the tissue bound carboxypeptidase M (kininase I) [58,63]. This elevation of des-Arg⁹kinins can be further enhanced by pre-treatment of animals with the kininase II inhibitor captopril [58]. Given the central role played by LPS in sepsis, these experimental data suggest that DABK may be involved in the pathology of this syndrome (see Section 6.1). Furthermore, fibrin degradation products that are released during sepsis will inhibit kininase II [64] thus further shifting the balance in favour of increased DABK production.

	5 Kinin B1 receptor distribution and function in the cardiovascular system

Top Abstract 1 Introduction 2 The kinin B1... 3 B1 receptor regulation:... 4 Synthesis of B1... 5 Kinin B1 receptor... 6 Role played by... 7 Conclusions References

 
B₁ receptor expression has been demonstrated in a variety of blood vessels, both veins and arteries, in several species. Expression has also been described in cardiac tissue and in the central nervous system. Thus, the major systems involved in the regulation of cardiovascular homeostasis have the capacity to express these receptors. Table 1 summarises the distribution of this receptor, with expression in ECs and VSMCs of several vessels ranging from large elastic arteries and veins to small muscular arteries. B₁ receptors are present on the ECs and VSMCs of the tunica media in the renal, femoral, carotid, coronary, vertebral, basilar and pericallosal arteries. The ECs of the large elastic pulmonary artery contain both B₁ and B₂ receptors. In the ECs and VSMCs of arterioles, B₂ receptor immunolabelling is more intense than that observed for B₁ receptors. Only B₂ receptor immunoreactivity was detected on the ECs of the large veins and in the aorta [65] (see Table 1 for further details).

View this table: [in this window] [in a new window]   Table 1 Kinin B1 receptor distribution and function in the cardiovascular systema

 
Studies attempting to identify the cell signalling pathways involved in B₁ receptor activity show some heterogeneity. Bovine pulmonary artery ECs synthesise prostaglandins in response to B₁ receptor activation [66,67]. In bovine aortic (BA) and rat microvascular coronary (RMC) ECs B₁ receptor activation results in intracellular accumulation of guanosine-3',5'-cyclic monophosphate (cGMP) [68,69] and is associated with B₁ receptor mRNA expression in RMCECs, human umbilical vein (HUV) ECs but paradoxically not in BAECs [70]. B₁ receptor-mediated vascular effects generally involve protein kinase C activation and calcium release [20,71] leading to the promotion of phosphoinositide hydrolysis by phospholipase C or arachidonic acid release by phospholipase A₂ [72].

5.1 Vascular reactivity: mechanisms and mediators
As mentioned earlier, the first described response to B₁ receptor activation was the contraction of rabbit aorta [2,3]. Since this initial observation the vasoactivity of B₁ receptor ligands has been described in several blood vessels, both arteries and veins, in a variety of species (Table 1). In general, vascular reactivity to B₁ receptor ligands is not present constitutively, but is acquired following incubation or application of an inflammatory insult.

5.1.1 B₁ receptor-mediated vasoconstriction
B₁ receptor ligands cause vasoconstriction of a range of blood vessels including rabbit aorta [2,71,73] rabbit mesenteric vein [74], pig renal vein [75] and human umbilical artery [76] and vein [22,77,78] (see Table 1). More recently vascular B₁ receptors have been identified in the rat isolated perfused kidney, activation of which lead to vasoconstriction [79]. B₁ receptor-mediated contraction of vascular smooth muscle is generally not dependent on an intact endothelium and involves a direct co-operation between protein kinase C and calcium release [20,35,71,80]. However, in the feline pulmonary vascular bed the vasoconstrictor response to DABK is mediated by the release of catecholamines and subsequent activation of -adrenergic receptors [81] whereas prostaglandin-dependent constriction is observed in rat portal vein [82].

5.1.2 B₁ receptor-mediated vasodilation
B₁ receptor-mediated vasodilator responses are usually an endothelium-dependent phenomenon as is the case in the rat coronary circulation [18], bovine [83], porcine [84] and human coronary arteries [85] and in rabbit mesenteric [86] and carotid arteries [87]. In the large part this endothelium-dependency can be attributed to activation of eNOS and subsequent release of vasodilator NO as demonstrated using NOS inhibitors in a wide range of blood vessels including the rabbit carotid [87], bovine [83] porcine [84] and human [85] coronary arteries [81] (see Table 1). B₁ receptor-mediated vasorelaxation in these latter studies [81,84,87,88] was not sensitive to cyclooxygenase inhibition and hence is unlikely to involve prostaglandin release. In contrast, B₁ receptor-mediated vasodilation of the rat coronary circulation [18] and rabbit mesenteric artery [86,89] involves the release of eicosanoids, in particular prostacyclin [18].

In some vessels, B₁ receptor-meditated vasodilation is endothelium-independent and this has been attributed to prostaglandin activity, e.g. in rabbit coeliac and mesenteric artery [90,91]. This functional and mechanistic diversity of B₁ receptor-mediated vascular reactivity may be related to species and/or regional variation and/or due to differences in local sensitivity to vasodilator mediators. B₁ receptors are positively coupled to phospholipase A₂ and thereby cause arachidonic acid release [35,72,80]. Despite this ability to elevate prostaglandin synthesis it is clear that functional responses depend entirely upon local prostaglandin sensitivity. For example, B₁ receptor stimulation causes prostaglandin synthesis and contraction of RASMC however the latter response is not blocked by indomethacin [71] a scenario repeated in bovine vascular tissue [92,93,67,83]. Indeed, the rabbit aorta does not relax in response to PGI₂ or PGE₂ [94]. In contrast, these prostaglandins produce potent vasodilation in rabbit mesenteric and coeliac arteries and rat coronary circulation [94–97], tissues in which B₁ receptor activation induces PGI₂ secretion [98,18] and a prostaglandin synthesis-dependent relaxant response. Taken together, not all endothelium-independent B₁ receptor-mediated relaxant responses are mediated by prostaglandins, despite the observations that prostaglandins are consistently released in response to B₁ receptor activation. This is possibly linked to the absence of specific prostaglandin receptors.

With few exceptions, it would seem that B₁ receptor activation consistently produces constrictor responses in veins and dilator responses in arteries. This pattern of reactivity is in line with a pro-inflammatory role of the B₁ receptor; i.e. arterial/arteriolar dilation associated with venoconstriction would lead to increased hydrostatic pressure thus enhancing plasma protein extravasation and the associated inflammatory events. Whilst this is an attractive hypothesis the observation that B₁ receptor activation does cause contraction of some arteries suggests that B₁ receptor-mediated control of vascular tone is a complex and still unresolved process.

5.2 Myocardial effects
The expression of kinin receptors by cardiomyocytes and cardiac conduction tissue has been demonstrated [99,100]. B₁ receptors are also expressed on sympathetic fibres in myocardial tissue the activation of which enhances noradrenaline outflow [101–103]. In contrast, other studies have shown that B₁ receptor activation reduces sympathetic outflow and this effect has been linked to the proposed protective activity of des-Arg⁹kinins in I/R injury [101]. B₂ receptor activation results in a prostaglandin-independent negative chronotropic effect in the canine sinus node [99]. Both B₁ and B₂ receptor stimulation can prolong the action potential duration in rat ventricular muscle [100] and this has been suggested to be a possible explanation for the anti-arrhythmic activity of the kinins.

5.3 Control of blood pressure
B₁ receptor-mediated hypotensive responses have been demonstrated and characterised in the rabbit [16], rat [18] pig [104], and dog [105]. The mechanism of this effect may be explained by the profile of reactivity within the vasculature, i.e. arterial dilation and venoconstriction. However, a reduction in heart rate was also observed in conjunction with the hypotensive effect of intravenously administered B₁ receptor agonists in the rabbit [106]. The authors suggest that early decreases in mean arterial pressure induced following B₁ receptor activation are due to the acute decreases in peripheral vascular resistance, presumably as a consequence of arterial dilation. However, the sustained hypotensive response was associated with a decrease in cardiac output attributed to decreases in cardiac contractility and heart rate. The B₁ receptor-mediated hypotensive response is generally only observed following an inflammatory stimulus e.g. endotoxin treatment, however some studies suggest that the hypotensive response occurs in ‘normal’ animals [105]. This may be an example of species variation, but is more likely to be associated with pre-existing infection [107].

A role for B₁ receptors in the central control of blood pressure (BP) has recently been reported. Caligiorne et al. [108] showed that DALBK microinjection into the nucleus tractus solitarii of Wistar Kyoto (WKY) rats prevented the cardiovascular effects of exogenous BK. Additionally it has been reported that central B₁ receptor blockade lowers BP in spontaneously hypertensive rats (SHR) but not in normotensive rats [109]. Support for a central rather than peripheral role of B₁ receptors in hypertension is provided by the fact that in a transgenic rat (mREN2)27 model of hypertension no expression of the B₁ receptor was detected in aorta, heart and kidneys [110]. However, it is possible that B₁ receptor expression is localised to other vascular beds, not tested, that contribute significantly to peripheral resistance, e.g. the mesenteric vasculature. A role for B₁ receptors in the central control of BP was confirmed by Emanueli et al. [111] who demonstrated that intracerebroventricular administration of B₁ receptor agonists increases BP in both WKY and SHR. Accordingly, B₁ receptor blockade or ‘knock-down’ with antisense oligonucleotides reduced BP in SHR, but not in WKY rats [111]. Furthermore, BP was elevated following central administration of a kininase II inhibitor and this effect was attenuated by central B₁ receptor blockade [111]. Together these results suggest that central B₁ receptors may play a role in the pathology of essential hypertension. In contrast however, Martins et al. [112] reported that neither DABK nor the B₁ receptor antagonist DALBK injected into the fourth cerebral ventricle altered the BP of WKY or SHR [113,114]. Normal regulation of BP however does not appear to involve B₁ receptors since B₁ receptor KO mice do not display a hyper- or hypotensive phenotype [115]. In contrast, B₂ receptor knockouts are predisposed to hypertension [116,117].

5.4 Inflammation and the microcirculation
Many of the effects of peripheral B₁ receptor activation are proinflammatory; vasodilation, increased blood flow [106,118], plasma protein extravasation [113,119], activation of leukocyte-endothelial cell interactions [28] and subsequent leukocyte accumulation [120]. B₁ receptor-mediated leukocyte recruitment was first demonstrated in our laboratory in 1996 [120]. In this study we showed that neutrophils accumulate in dorsal air pouches of mice when treated locally with IL-1β (4 h). This leukocyte accumulation was partially inhibited by B₁ receptor blockade with DALBK, but not by B₂ receptor blockade with HOE140. DABK itself also caused leukocyte migration in this model, but only in mice that had been previously treated (24 h) with IL-1β. DABK-induced leukocyte recruitment was inhibited by selective antagonists of the receptors for the neuropeptides substance P and calcitonin gene-related peptide (CGRP) [120] indicating that DABK, directly or indirectly, activates sensory C-fibres to release neuropeptides that, in turn, stimulate leukocyte recruitment. Support for a role for B₁ receptors in the cellular component of an inflammatory response was provided in a recent study in which a less specific inflammatory stimulus was used, i.e. sephadex bead-induced pulmonary leukocyte accumulation in guinea pigs was inhibited by B₁ receptor antagonism [114]. B₁ receptor-mediated leukocyte recruitment has also been demonstrated in a separate study by Vianna and Calixto [113]. In this study intrathoracic injection of DABK produced an inflammatory response characterized by plasma protein extravasation and leukocyte accumulation. In contrast to our study, these effects were observed in ‘normal’ animals suggesting that, in this model, B₁ receptors are either constitutively expressed or were already induced. This discrepancy is hard to explain, but may be an example of regional and/or species variation. However, it is more likely associated with a pre-existing inflammatory state (e.g. infection) that would lead to the appearance of pre-formed B₁ receptors. Similar to our study, the DABK-induced leukocyte recruitment was inhibited by B₁ receptor blockade and by neurokinin and CGRP receptor antagonists [113].

Since our 1996 study we have confirmed our findings and extended them to the microvasculature of mouse mesentery [28]. This investigation has been performed at the level of the leukocyte-endothelial cell interaction in post-capillary venules using the intravital microscopy technique. We demonstrated that B₁ receptor activation induces all three phases of the leukocyte recruitment process: cell rolling, adhesion and emigration (Fig. 1). This is in contrast to other agents which display specificity in their action, e.g. histamine which preferentially enhances leukocyte rolling [121]. Additionally, this functional activity was temporally associated with receptor mRNA and protein expression. Modest basal expression of the B₁ receptor mRNA was detected in saline injected animals, however, this was not associated with protein expression [28]. It is possible that B₁ receptor mRNA is constitutively expressed but an appropriate inflammatory stimulus is required to achieve optimal translation. In this model, DABK-induced effects were independent of B₂ receptor activation since experiments using HOE 140 or B₂ receptor knockout mice had no effect on the magnitude of the cellular response. As illustrated in Fig. 2, we showed that the DABK-induced leukocyte trafficking responses involved the release of neuropeptides from C fibers, since capsaicin treatment inhibited the responses. Furthermore, mast cells were involved in the response since DABK-induced leukocyte trafficking was reduced following mast cell depletion with compound 48/80 and DABK treatment was shown histologically to induce mast cell degranulation. These findings provide clear evidence that B₁ receptors play an important role in the initiation of leukocyte recruitment during an inflammatory response and this effect appears to involve the activation of sensory C fibres and/or mast cells. The exact relationship and sequence of events between the C-fibre- and mast cell-dependent pathways is less clear but certain possibilities are addressed in Fig. 2.

View larger version (104K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 1 Intravital video-microscopy images of leukocyte trafficking responses in mouse mesenteric post-capillary venules in vivo in response to (A) saline (0.25 ml, i.p., 2 h), (B) des-Arg9bradykinin (30 nmol, i.p., 2 h), (C) des-Arg9bradykinin (30 nmol, i.p., 4 h). Mice were anesthetized with diazepam (60 mg/kg s.c.) and Hypnorm® (0.7 mg/kg fentanyl cirate and 20 mg/kg fluanisone i.m). A Zeiss Axioskop ‘FS’ with a water-immersion objective lens (magnification of x40; Zeiss) and an eyepiece (x10 magnification; Zeiss) was used to observe the microcirculation. The acquired images were displayed onto a colour video monitor and recorded for subsequent off-line analysis. Mesenteries were superfused with bicarbonate-buffered solution at 37°C. Images reprinted with permission from the Journal of Experimental Medicine.

 

View larger version (36K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 2 Possible sites of action of des-Arg9bradykinin (DABK) in the initiation of leukocyte trafficking. DABK and Lys-DABK act on B1 receptors possibly expressed on sensory neurones and mast cells to activate the process of leukocyte trafficking. Kinin-mediated leukocyte recruitment may involve, as intermediaries, release of substance P (SP) from sensory neurons and histamine (hist) from mast cells, which will active NK1 or H1 receptors, respectively, on either the endothelium, mast cell or sensory neurone.

 
The site of B₁ receptor expression is unclear from these studies. There are some in vitro observations suggesting B₁ receptor expression on phagocytic cells and lymphocytes. For instance, human neutrophils secrete elastase in response to BK or Lys-DABK mediated by B₂ and B₁ receptors, respectively [122]. In addition, Lys-DABK causes increased permeability of an endothelial layer maintained in vitro only in the presence of neutrophils [122]. These neutrophils were naïve, non-activated cells hence suggesting that B₁ receptors are constitutively expressed on these cells. Circulating lymphocytes also appear to exhibit a chemokinetic response to kinins via the stimulation of B₁ receptors in vitro [123]. Furthermore, B₁ receptor induction has been shown to occur on T lymphocytes during the course of multiple sclerosis, and when activated mediate a reduction in T-cell migration in vitro [124]. However, in a recent study we showed that DABK had no effect on various parameters of neutrophil function in vitro [120]. At the present time it remains unclear as to whether B₁ receptors are present on leukocytes.

In contrast to the above studies of B₁ receptor-mediated inflammation, B₂ receptors appear to play little role in the cellular component of a vascular inflammatory response. Whilst B₂ receptor-mediated effects such as plasma protein extravasation and adhesion molecule expression have been reported, BK produces no cellular response when injected into the skin [1]. This is confirmed by the observation that very high doses of BK are required to promote leukocyte–endothelial cell interactions in rat mesenteric post-capillary venules; doses 100–500 times higher than that required to promote changes in blood flow [125]. Therefore it appears that B₂ receptors may only have a small role to play in the cellular component of the inflammatory response.

	6 Role played by B1 receptors in pathophysiology of the cardiovascular system

Top Abstract 1 Introduction 2 The kinin B1... 3 B1 receptor regulation:... 4 Synthesis of B1... 5 Kinin B1 receptor... 6 Role played by... 7 Conclusions References

 
Pathological activation of the kallikrein–kinin system generally occurs during situations of stress such as inflammation or shock (e.g. following a pathogenic or chemical insult). This acute response consists of the activation of PK, leading to BK generation. Release of BK and subsequent activation of B₂ receptors has been suggested to play an important role in acute inflammation and the immediate hypotensive response to endotoxin [1]. However, it now appears that the subsequent formation of des-Arg⁹kinins and induction and activation of B₁ receptors may also play an important role in the pathology of human disease, particularly those diseases in which a vascular inflammatory component exists.

6.1 Sepsis and the kallikrein–kinin system
Sepsis is defined as the systemic inflammatory response syndrome (SIRS) that results from infection and is referred to as ‘septic shock’ when accompanied by hypotension that is unresponsive to fluid therapy [126]. Endotoxins, released from gram-negative bacteria, are thought to play an integral role in the pathogenesis of sepsis. Exposure to gram-negative or gram-positive bacteria, fungi or proteoglycan polysaccharides can trigger the release of inflammatory substances including kallikrein from infiltrating leukocytes, platelets and ECs, as well as directly activating the kallikrein–kinin system leading to increased kinin synthesis [126]. Kinins appear to be particularly important in the pathogenesis of SIRS and sepsis when endotoxin is the critical pathogen [127]. The early peripheral vascular changes accompanying endotoxic shock include a fall in blood pressure. A key feature of endotoxemia is a hypodynamic state which alters the distribution of blood to exchange vessels in tissues and organs throughout the body. One such example of this disordered autoregulation in sepsis is the coronary microcirculation [128,129]. This phenomenon is thought to be due partly to the release of NO from iNOS expressed in vascular smooth muscle [128], an important mediator of sepsis-induced hypotension [130], however NO-independent mechanisms exist but remain to be elucidated [131,132]. Several studies support a role for the B₁ receptor which has been implicated in the regulation of the coronary circulation in rat and rabbit models of endotoxemia [18,16,133]. Infusion of BK or DABK results in cardiovascular changes, particularly hypotension, similar to those occurring in endotoxic shock [18,134]. In animal models, endotoxin causes rapid activation of the kallikrein–kinin system increasing kinin levels [135,136]. This effect appears to be specific to LPS as the monophosphoryl lipid A derivative of bacterial LPS fails to induce B₁ receptor-dependent responses to DABK in the rabbit in vivo [137]. Similarly, the pathological response to intravenous endotoxin in healthy human volunteers [138] is associated with activation of the kallikrein–kinin systems. In addition, consumption of pre-kallikrein and HMWK is also increased in patients with endotoxemia, and this is particularly true for patients with septic shock (or hypotensive sepsis) compared to those with uncomplicated sepsis [139–142].

6.1.1 Kinin receptors and sepsis
Support for a role of kinin receptors in the hypotensive response in sepsis is provided by several studies demonstrating a partial restoration of blood pressure following treatment with kinin receptor antagonists. Endotoxin treatment produces a profound biphasic hypotensive response, a brief early phase followed by a prolonged late phase. The first phase is sensitive to B₂ receptor blockade [136,143], but not affected by B₁ receptor antagonists (McLean, Perretti and Ahluwalia, unpublished observation). The prolonged phase, which is the stage at which patients present in the clinic, has been extensively studied and is known to be partially dependent on enhanced NO production from the induction of iNOS [130]. In a recent study [18] we showed that B₁ receptor antagonists produced a partial reversal of the prolonged phase of endotoxin-induced hypotension. The inhibition of ACE/kininase II with captopril did not appear to markedly affect the role of B₁ receptors in hypotension in this model [18]. Mice lacking the gene for the B₁ receptor have been developed [115] and a full characterization of the responses to bacterial infection and endotoxic shock in these animals is needed. It was suggested that the immediate hypotensive response to endotoxin is markedly blunted in these animals [115]. This finding contrasts the observation made in the rat, and requires confirmation in a full study, but certainly suggests that the B₁ receptor is involved in the hypotensive response to endotoxin.

6.1.2 Kinin receptor antagonists in the treatment of sepsis
A role for kinin receptors in endotoxic shock, while an attractive target, is not yet certain because specific metabolically stable kinin receptor antagonists have only recently been made available. The following sections describe some of the findings arising from studies of kinin receptor antagonists in animal models of endotoxic shock and human sepsis.

6.1.2.1 B₂ receptor antagonists
Given the evidence implicating kinins in the pathogenesis of sepsis it is not surprising that pre-formed B₂ receptors have been suggested to play a role in certain aspects of the septic syndrome. However, reports investigating the effects of B₂ receptor antagonism in models of endotoxemia are conflicting showing both beneficial effects and negative efficacy. One of the first studies to investigate the effect of kinin receptor blockade in endotoxic shock was that of Wilson et al. [136] who tested the B₂ receptor antagonist D-Arg-Hyp³-D-Phe⁷-bradykinin (NPC 567). In this study administration of LPS to rats resulted in an increase in circulating bradykinin and prostaglandin levels and a profound hypotensive response. NPC 567 infusion dramatically reduced mortality from 100 to 50% at 24 h which was accompanied by a significant reduction in 6-keto-PGF₁ levels and partial reversal of the hypotensive effects. Other studies confirm beneficial effects of B₂ receptor blockade in sepsis [144,145]. However, there are also contrary reports indicating no benefit of B₂ receptor antagonism. In particular, the study by Feletou et al. [146] demonstrated that LPS-induced hypotension, metabolic acidosis and leukopenia in rabbits was unaffected by the B₂ receptor antagonist S 16118. Furthermore, in mice, LPS administration induced over 90% mortality at 96 h which was not reduced by S 16118 [146]. Other studies in rodents report a negative efficacy for B₂ receptor blockade alone in experimental endotoxic shock [147,148] although a beneficial effect was observed when used in combination with leukocyte recruitment inhibitors (NPC 15669) [148].

6.1.2.2 B₁ receptor antagonists
B₁ receptor-mediated hypotensive responses have been demonstrated and characterised in rabbit [16], rat [18] and pig [104] models of endotoxemia indicating a potential role for this receptor in the hypotensive response to endotoxin. Administration of B₁ receptor antagonists blocks the hypotensive effect of exogenously administered B₁ receptor agonists [16,18]. The only report investigating the effect of B₁ receptor blockade on the endotoxic shock-associated hypotension was performed recently in our laboratory [18]. We showed that B₁ receptor blockade with DALBK or des-arg¹⁰HOE140 produced a modest reversal (5–9%) of endotoxin-induced hypotension. Therefore activation of B₁ receptors may have a modest role to play in the vascular changes associated with endotoxemia, however the possibility of synergism with other therapies has not been tested. The effect of selective B₁ receptor antagonists on mortality associated with endotoxemia is unclear. Siebeck et al. [145] showed that B₂ receptor blockade attenuates endotoxin-induced mortality in pigs, whereas additional B₁ receptor blockade seemed to reverse these beneficial effects [145]. However, the effect of B₁ receptor blockers alone was not tested. The reasons for this apparent contradiction regarding the role of B₁ receptors is unclear but may be related to species differences. The pattern of B₁ receptor expression in endotoxic pigs is reportedly confined to the smooth muscle with no endothelial expression [63]. In contrast, endotoxin-induced, B₁ receptor-mediated vasodilation in rat vessels is endothelium-dependent [18] similar to human coronary arteries [85]. However, it is possible that B₁ receptor activation is protective, at least in the porcine model of endotoxic shock, which may or may not be relevant in other species. Alternatively, the level of B₁ receptor blockade may be important; partial inhibition may be beneficial whereas complete blockade is detrimental. Further studies with selective metabolically stable kinin receptor antagonists are required to address this controversy.

6.1.2.3 Mixed kinin receptor antagonists
It is possible that the apparent contradictory findings with kinin receptor antagonists lie in their receptor selectivity. Certain peptidic B₂ receptor antagonists are non-selective and have some efficacy at B₁ receptors in vivo. CP-0127 is a peptide dimer of two single chain BK antagonists linked together creating a compound with high potency in vitro [149] and long duration of action in vivo [143]. The pharmacology of this compound is unique in that it appears to be a specific B₂ receptor antagonist in vitro [150]. However, in vivo it behaves as a B₂ receptor antagonist with moderate B₁ receptor antagonist activity (Cheronis, J.C. 1999. Personal communication). CP-0127 itself does not have B₁ receptor antagonist activity but its two metabolites, the mono and bis-des-Arg derivatives do. Their potency is relatively low but they are more stable and consequently accumulate (Cheronis, J.C. 1999. Personal communication). Administration of such compounds (e.g. CP-0127, NPC-567) inhibit hypotension and improve survival in rats and rabbits challenged with endotoxin [136,143]. This improvement over B₂ receptor blockade alone would imply that compounds possessing affinity at both kinin receptors may prove advantageous in the therapy of sepsis [151]. Indeed, CP-0127 marginally improves survival in patients with gram-negative sepsis [152], and it is possible that this beneficial effect is correlated with the efficacy of this compound at B₁ receptors.

6.2 I/R injury
I/R injury is an inflammatory state also associated with B₁ receptor induction. In both in vitro and in vivo models of myocardial I/R functional B₁ receptor expression is induced [153]. In rat isolated hearts ischemia-induces B₁ receptors that upon activation modulate noradrenaline release or preserve endothelium-dependent vasodilation [101,103,154]. Further support for a role of kinins in I/R injury is provided by the demonstration that the kallikrein–kinin system in the heart is activated as demonstrated by an increase in the levels of kinins in the effluent of isolated perfused hearts [41,155]. Similarly kinin levels are elevated in in vivo myocardial I/R injury; an effect further increased by kininase II inhibition [156,157].

Recent studies indicate that BK, acting via B₂ receptors, has a protective effect in I/R injury of the rat mesenteric microcirculation [158] and rabbit myocardium [159]. Additionally treatment with angiotensin-converting enzyme inhibitors further attenuate the extent of I/R injury, an effect associated with elevated levels of endogenous kinins [159]. Indeed, intracoronary perfusion of exogenous BK is protective against I/R-induced ventricular fibrillation [160,161]. B₁ receptors have also been suggested to play a protective role since B₁ receptor antagonism blocks DABK- or BK-induced decreases of I/R-induced noradrenaline outflow and arrhythmia [101].

That kinins exert a protective effect in I/R is surprising because of their well-known proinflammatory actions. Especially since B₂ receptors have been implicated in the pathogenesis of post ischemic pancreatitis [162] and the fact that B₁ receptors play a role in initiation of the leukocyte–endothelial interaction that occurs in global ischemia of the brain [163]. However, in a rat model of cerebral artery occlusion, opposing effects of B₂ and B₁ receptor antagonism have been described [164]. Antagonism of B₂ receptors reduced cerebral infarct whereas B₁ receptor blockade reversed the beneficial effect of the B₂ receptor antagonist [164]. In this model B₁ and B₂ receptors have differential effects on ischemic brain pathology.

Therefore, it appears that kinin receptor activation has the potential to modulate I/R injury. Further studies are required to fully understand the mechanisms and functional relevance of these observed effects and to determine under which conditions these effects are protective or contributory to the pathology of I/R injury.

6.2.1 Ischaemic preconditioning
Activation of the kallikrein–kinin system is necessary for the cardioprotective effect of preconditioning and involves activation of both B₂ [165] and B₁ [101,154] receptors. The use of selective antagonists has shown that B₂ receptor activation mediates the benefits of ischaemic preconditioning on certain features of I/R injury; reduced arrhythmias [166], reduced infarct size [167] and improvement of post-ischaemic ventricular recovery [168]. B₁ receptor activation appears to be important in the protection provided by ischaemic preconditioning on endothelial function [154] as well as inhibiting noradrenaline overflow and preventing ventricular fibrillation at reperfusion [101]. In contrast to their role in I/R injury, which is less clear, B₁ receptors are clearly important in the protection afforded by ischaemic preconditioning.

6.3 Atheromatous disease
Immunoreactivity for the human B₁ receptor is markedly increased in atheromatous plaques of the coronary, vertebral, femoral and pericallosal arteries [65]. Intense labelling for B₁ receptors was shown to be most apparent on the ECs, foamy macrophages, infiltrating leukocytes and in proliferating SMCs. Immunoreactive B₂ receptors were also expressed in these lesions, but with a consistently lower intensity relative to the B₁ receptor. Pilot studies in the rabbit on the effects of high dietary cholesterol on B₁ receptor expression in cardiac tissue were negative [14] whilst in the same study, endotoxin treatment caused marked cardiac B₁ receptor expression. Taken together these studies suggest that up-regulation of B₁ receptors expression may occur as a result of the inflammatory nature of atherosclerosis, but not simply as a result of hypercholesterolemia. The precise role of B₁ receptors (contributory or protective) in the development of ischaemic heart disease is difficult to predict and requires further study.

6.4 Angioplasty
Evidence suggesting a role for B₁ receptors in the pathogenesis of angioplasty-induced vascular injury was provided in a recent study by Pruneau et al. [169]. In this study balloon catheter injury to the rabbit carotid artery led to the development of a contractile response to the B₁ receptor agonist DABK. This induction of reactivity to DABK was associated with the proliferation of SMCs but a causal relationship between the two findings was not demonstrated [169]. B₁ receptor stimulation has been shown to cause contraction and DNA synthesis in cytokine treated rabbit aortic SMCs, the latter effect being unique to cytokine-treated cells [20]. As such, B₁ receptor induction may play a role, in concert, in the altered reactivity and hypertrophic medial responses to injury in arteries following angioplasty although further studies are required to confirm this. In contrast, B₁ receptor activation also leads to suppression of DNA synthesis in PDGF-stimulated rat mesenteric artery SMCs [170], although the significance of this finding remains to be determined.

6.5 Other diseases
The role played by B₁ receptors in other diseases of the cardiovascular system such as hypertension, cardiac failure and their associated complications is unknown. It is interesting to note that increased production of inflammatory cytokines occurs in human cardiac failure [171] that would be expected to stimulate wide spread B₁ receptor induction.

Polymorphisms in the human B₁ receptor gene have been identified and appear to be associated with the risk of end-stage renal disease [172,173]. An allele in which a single base substitution (G699C) occurs in the putative promoter region with significantly lower frequency in a population of renal failure patients and determines an increased activity of promoter function [173]. B₁ receptor polymorphisms have been suggested to have a protective effect in the development of end-stage renal disease [172]. Whether B₁ receptor polymorphisms exist for other cardiovascular diseases remains to be determined

	7 Conclusions

Top Abstract 1 Introduction 2 The kinin B1... 3 B1 receptor regulation:... 4 Synthesis of B1... 5 Kinin B1 receptor... 6 Role played by... 7 Conclusions References

 
B₁ receptors are involved in certain cardiovascular inflammatory pathologies such as endotoxic shock, atheromatous disease, and myocardial ischaemia. Furthermore, the inducibility of the receptor makes it an attractive target for therapeutic interventions. Drug development efforts, however, will need to be acutely aware of the possibility that activation of B₁ receptors may be pathogenic or protective depending on the disease and tissue affected.

Time for primary review 32 days.

	Acknowledgements

 
Dr McLean and some of the authors' work herein is supported by the British Heart Foundation (BHF, PG#97013). Dr Ahluwalia is funded by a BHF Intermediate Fellowship and Dr Perretti is a Research Fellow of the Arthritis Research Campaign.

	References

Top Abstract 1 Introduction 2 The kinin B1... 3 B1 receptor regulation:... 4 Synthesis of B1... 5 Kinin B1 receptor... 6 Role played by... 7 Conclusions References

 

1. Bhoola K.D., Figueroa C.D., Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev (1992) 44:1–80.[Web of Science][Medline]
2. Regoli D., Barabe J., Park W.K. Receptors for bradykinin in rabbit aortae. Can J Physiol Pharmacol (1977) 55:855–867.[Web of Science][Medline]
3. Regoli D., Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev (1980) 32:1–46.[Web of Science][Medline]
4. Fathy D.B., Mathis S.A., Leeb T., Leeb-Lundberg L.M. A single position in the third transmembrane domains of the human B₁ and B2 bradykinin receptors is adjacent to and discriminates between the C-terminal residues of subtype-selective ligands. J Biol Chem (1998) 273:12210–12218.[Abstract/Free Full Text]
5. Marceau F., Hess J.F., Bachvarov D.R. The B₁ receptors for kinins. Pharmacol Rev (1998) 50:357–386.[Abstract/Free Full Text]
6. Regoli D., Nsa A.S., Rizzi A., Gobeil F.J. Bradykinin receptors and their antagonists. Eur J Pharmacol (1998) 348:1–10.[CrossRef][Web of Science][Medline]
7. Phillips E., Conder M.J., Bevan S., McIntyre P., Webb M. Expression of functional bradykinin receptors in Xenopus oocytes. J Neurochem (1992) 58:243–249.[CrossRef][Web of Science][Medline]
8. Webb M., McIntyre P., Phillips E. B₁ and B₂ bradykinin receptors encoded by distinct mRNAs. J Neurochem (1994) 62:1247–1253.[Web of Science][Medline]
9. Menke J.G., Borkowski J.A., Bierilo K.K., et al. Expression cloning of a human B₁ bradykinin receptor. J Biol Chem (1994) 269:21583–21586.[Abstract/Free Full Text]
10. Pesquero J.B., Pesquero J.L., Oliveira S.M., et al. Molecular cloning and functional characterization of a mouse bradykinin B₁ receptor gene. Biochem Biophys Res Commun (1996) 220:219–225.[CrossRef][Web of Science][Medline]
11. Pesquero J.B., Lindsey C.J., Zeh K., et al. Molecular structure and expression of rat bradykinin B₂ receptor gene. Evidence for alternative splicing. J Biol Chem (1994) 269:26920–26925.[Abstract/Free Full Text]
12. MacNeil T., Bierilo K.K., Menke J.G., Hess J.F. Cloning and pharmacological characterization of a rabbit bradykinin B₁ receptor. Biochim Biophys Acta (1995) 1264:223–228.[Medline]
13. Fathy D.B., Kyle D.J., Leeb-Lundberg L.M. High-affinity binding of peptide agonists to the human B₁ bradykinin receptor depends on interaction between the peptide N-terminal L-lysine and the fourth extracellular domain of the receptor. Mol Pharmacol (2000) 57(1):171–179.[Abstract/Free Full Text]
14. Marceau F. The kinin system. Farmer S.G., ed. (1997) San Diego: Academic Press. 143–156.
15. Bouthillier J., Deblois D., Marceau F. Studies on the induction of pharmacological responses to des-Arg⁹-bradykinin in vitro and in vivo. Br J Pharmacol (1987) 92:257–264.[Web of Science][Medline]
16. Regoli D.C., Marceau F., Lavigne J. Induction of B₁-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur J Pharmacol (1981) 71:105–115.[CrossRef][Web of Science][Medline]
17. Deblois D., Bouthillier J., Marceau F. Effect of glucocorticoids, monokines and growth factors on the spontaneously developing responses of the rabbit isolated aorta to des-Arg⁹-bradykinin. Br J Pharmacol (1988) 93:969–977.[Web of Science][Medline]
18. McLean P.G., Perretti M., Ahluwalia A. Inducible expression of the kinin B₁ receptor in the endotoxemic heart: mechanisms of des-Arg⁹bradykinin-induced coronary vasodilation. Br J Pharmacol (1999) 128:275–282.[CrossRef][Web of Science][Medline]
19. Deblois D., Bouthillier J., Marceau F. Pulse exposure to protein synthesis inhibitors enhances vascular responses to des-Arg⁹-bradykinin: possible role of interleukin-1. Br J Pharmacol (1991) 103:1057–1066.[Web of Science][Medline]
20. Levesque L., Larrivee J.F., Bachvarov D.R., et al. Regulation of kinin-induced contraction and DNA synthesis by inflammatory cytokines in the smooth muscle of the rabbit aorta. Br J Pharmacol (1995) 116:1673–1679.[Web of Science][Medline]
21. De Kimpe S.J., Tielemans W., Van Heuven-Nolsen D., Nijkamp F.P. Reversal of bradykinin-induced relaxation to contraction after interferon-gamma in bovine isolated mesenteric arteries. Eur J Pharmacol (1994) 261:111–120.[CrossRef][Web of Science][Medline]
22. Sardi S.P., Perez H., Antunez P., Rothlin R.P. Bradykinin B₁ receptors in human umbilical vein. Eur J Pharmacol (1997) 321:33–38.[CrossRef][Web of Science][Medline]
23. Tsukagoshi H., Shimizu Y., Horie T., et al. Regulation by interleukin-1beta of gene expression of bradykinin B₁ receptor in MH-S murine alveolar macrophage cell line. Biochem Biophys Res Commun (1999) 259:476–482.[CrossRef][Web of Science][Medline]
24. Schanstra J.P., Bataille E., Marin C.M., et al. The B₁-agonist [des-Arg¹⁰]-kallidin activates transcription factor NF-kappaB and induces homologous upregulation of the bradykinin B₁-receptor in cultured human lung fibroblasts. J Clin Invest (1998) 101:2080–2091.[Web of Science][Medline]
25. Zhou X., Polgar P., Taylor L. Roles for interleukin-1beta, phorbol ester and a post-transcriptional regulator in the control of bradykinin B₁ receptor gene expression. Biochem J (1998) 330:361–366.[Web of Science][Medline]
26. Deblois D., Bouthillier J., Marceau F. Pharmacological modulation of the up-regulated responses to des-Arg⁹-bradykinin in vivo and in vitro. Immunopharmacology (1989) 17:187–198.[CrossRef][Web of Science][Medline]
27. Lagneux C., Innocenti-Francillard P., Godin-Ribuot D., Bader M., Ribuot C. Heat stress-induced B₁ receptor synthesis in the rat: an ex vivo study. Br J Pharmacol (1998) 125:812–816.[CrossRef][Web of Science][Medline]
28. McLean P.G., Ahluwalia A., Perretti M. Association between kinin B₁ receptor expression and leukocyte trafficking across mouse mesenteric post-capillary venules. J Exp Med (2000) 192:367–380.[Abstract/Free Full Text]
29. Ni A., Chao L., Chao J. Transcription factor nuclear factor kappaB regulates the inducible expression of the human B₁ receptor gene in inflammation. J Biol Chem (1998) 273:2784–2791.[Abstract/Free Full Text]
30. Campos M.M., Souza G.E., Calixto J.B. In vivo B₁ kinin-receptor upregulation. Br J Pharmacol (1999) 127:1851–1859.[CrossRef][Web of Science][Medline]
31. Phagoo S.B., Poole S., Leeb-Lundberg L.M. Autoregulation of bradykinin receptors: agonists in the presence of interleukin-1beta shift the repertoire of receptor subtypes from B₂ to B₁ in human lung fibroblasts. Mol Pharmacol (1999) 56:325–333.[Abstract/Free Full Text]
32. Schanstra J.P., Marin-Castano M.E., Alric C., et al. Homologous and heterologous induction of the human bradykinin B₁-receptor and B₁-receptor localisation along the rat nephron. Immunopharmacology (1999) 45:29–34.[CrossRef][Web of Science][Medline]
33. Austin C.E., Faussner A., Robinson H.E., et al. Stable expression of the human kinin B₁ receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways. J Biol Chem (1997) 272:11420–11425.[Abstract/Free Full Text]
34. Faussner A., Proud D., Towns M., Bathon J.M. Influence of the cytosolic carboxyl termini of human B₁ and B₂ kinin receptors on receptor sequestration, ligand internalization, and signal transduction. J Biol Chem (1998) 273:2617–2623.[Abstract/Free Full Text]
35. Smith J.A., Webb C., Holford J., Burgess G.M. Signal transduction pathways for B₁ and B₂ bradykinin receptors in bovine pulmonary artery endothelial cells. Mol Pharmacol (1995) 47:525–534.[Abstract]
36. Hausdorff W.P., Bouvier M., O'Dowd B.F., et al. Phosphorylation sites on two domains of the beta 2-adrenergic receptor are involved in distinct pathways of receptor desensitization. J Biol Chem (1989) 264:12657–12665.[Abstract/Free Full Text]
37. Lohse M.J. Molecular mechanisms of membrane receptor desensitization. Biochim Biophys Acta (1993) 1179:171–188.[Medline]
38. Kaplan A.P., Joseph K., Shibayama Y., et al. The intrinsic coagulation/kinin-forming cascade: assembly in plasma and cell surfaces in inflammation. Adv Immunol (1997) 66:225–272.[Web of Science][Medline]
39. Fong D., Smith D.I., Hsieh W.T. The human kininogen gene (KNG) mapped to chromosome 3q26-qter by analysis of somatic cell hybrids using the polymerase chain reaction. Hum Genet (1991) 87:189–192.[CrossRef][Web of Science][Medline]
40. Margolius H.S. Theodore Cooper Memorial Lecture. Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension (1995) 26:221–229.[Abstract/Free Full Text]
41. Lamontagne D., Nadeau R., Adam A. Effect of enalaprilat on bradykinin and des-Arg⁹-bradykinin release following reperfusion of the ischaemic rat heart. Br J Pharmacol (1995) 115:476–478.[Web of Science][Medline]
42. Ben Nasr A., Herwald H., Sjobring U., et al. Absorption of kininogen from human plasma by Streptococcus pyogenes is followed by the release of bradykinin. Biochem J (1997) 326:657–660.[Web of Science][Medline]
43. Proud D., Togias A., Naclerio R.M., et al. Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest (1983) 72:1678–1685.[Web of Science][Medline]
44. Wu H.F., Venezie R.D., Cohen W.M., et al. Identification of tissue kallikrein messenger RNA in human neutrophils. Agents Actions (1993) 38:27–31.[CrossRef][Web of Science][Medline]
45. Chen L.M., Song Q., Chao L., Chao J. Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney. Kidney Int (1995) 48:690–697.[Web of Science][Medline]
46. Chen L.M., Richards G.P., Chao L., Chao J. Molecular cloning, purification and in situ localization of human colon kallikrein. Biochem J (1995) 307:481–486.[Web of Science][Medline]
47. Nolly H., Carretero O.A., Scicli A.G. Kallikrein release by vascular tissue. Am J Physiol (1993) 265:H1209–H1214.[Web of Science][Medline]
48. Oza N.B., Schwartz J.H., Goud H.D., Levinsky N.G. Rat aortic smooth muscle cells in culture express kallikrein, kininogen, and bradykininase activity. J Clin Invest (1990) 85:597–600.[Web of Science][Medline]
49. Decarie A., Raymond P., Gervais N., Couture R., Adam A. Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg⁹]BK: influence of enalaprilat. Am J Physiol (1996) 271:H1340–H1347.[Web of Science][Medline]
50. Erdos E.G. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol (1990) 15(6):S20–S24.[Web of Science][Medline]
51. Blais C.J., Drapeau G., Raymond P., et al. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. Am J Physiol (1997) 273:H2263–H2271.[Web of Science][Medline]
52. Prechel M.M., Orawski A.T., Maggiora L.L., Simmons W.H. Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung. J Pharmacol Exp Ther (1995) 275:1136–1142.[Abstract/Free Full Text]
53. Ersahin C., Simmons W.H. Inhibition of both aminopeptidase P and angiotensin-converting enzyme prevents bradykinin degradation in the rat coronary circulation. J Cardiovasc Pharmacol (1997) 30:96–101.[CrossRef][Web of Science][Medline]
54. Ward P.E. Bradykinin antagonists. Burch R.M., ed. (1991) New York: Marcel Dekker. 147–170.
55. Zolfaghari R., Little D., Baker C.R., Canizaro P.C., Behal F.J. Human lung membrane-bound neutral metallo-endopeptidase-catalyzed hydrolysis of bradykinin. Enzyme (1989) 42:160–173.[Web of Science][Medline]
56. Hoang M.V., Turner A.J. Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin. Biochem J (1997) 327:23–26.[Web of Science][Medline]
57. Johnson G.D., Stevenson T., Ahn K. Hydrolysis of peptide hormones by endothelin-converting enzyme-1. J Biol Chem (1999) 274:4053–4058.[Abstract/Free Full Text]
58. Raymond P., Drapeau G., Raut R., et al. Quantification of des-Arg⁹-bradykinin using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation. J Immunol Methods (1995) 180:247–257.[CrossRef][Web of Science][Medline]
59. Ahluwalia A., Perretti M. B₁ receptors as a new inflammatory target. Trends Pharmacol Sci (1999) 20:100–104.[CrossRef][Medline]
60. Takano M., Yokoyama K., Yayama K., Okamoto H. Murine fibroblasts synthesize and secrete kininogen in response to cyclic-AMP, prostaglandin E2 and tumor necrosis factor. Biochim Biophys Acta (1995) 1265:189–195.[Medline]
61. Cumming A.D., Walsh T., Wojtacha D., et al. Expression of tissue kallikrein in human kidney. Clin Sci (Colch) (1994) 87:5–11.[Medline]
62. Kozik A., Moore R.B., Potempa J., et al. A novel mechanism for bradykinin production at inflammatory sites. J Biol Chem (1998) 273:33224–33229.[Abstract/Free Full Text]
63. Schremmer-Danninger E., Offner A., Siebeck M., Roscher A.A. B₁ bradykinin receptors and carboxypeptidase M are both upregulated in the aorta of pigs after LPS infusion. Biochem Biophys Res Commun (1998) 243:246–252.[CrossRef][Web of Science][Medline]
64. Saldeen T., Ryan J.W., Berryer P. A peptide derived from fibrin(ogen) inhibits angiotensin converting enzyme and potentiates the effects of bradykinin. Thromb Res (1981) 23:465–470.[CrossRef][Web of Science][Medline]
65. Raidoo D.M., Ramsaroop R., Naidoo S., Muller-Esterl W., Bhoola K.D. Kinin receptors in human vascular tissue: their role in atheromatous disease. Immunopharmacology (1997) 36:153–160.[CrossRef][Web of Science][Medline]
66. Conklin B.R., Burch R.M., Steranka L.R., Axelrod J. Distinct bradykinin receptors mediate stimulation of prostaglandin synthesis by endothelial cells and fibroblasts. J Pharmacol Exp Ther (1988) 244:646–649.[Abstract/Free Full Text]
67. Cahill M., Fishman J.B., Polgar P. Effect of des arginine⁹-bradykinin and other bradykinin fragments on the synthesis of prostacyclin and the binding of bradykinin by vascular cells in culture. Agents Actions (1988) 24:224–231.[CrossRef][Web of Science][Medline]
68. Wirth K.J., Scholkens B.A., Wiemer G. The bradykinin B₂ receptor antagonist WIN 64338 inhibits the effect of des-Arg⁹-bradykinin in endothelial cells. Eur J Pharmacol (1994) 288:R1–R2.[CrossRef][Web of Science][Medline]
69. Wiemer G., Wirth K. Production of cyclic GMP via activation of B₁ and B₂ kinin receptors in cultured bovine aortic endothelial cells. J Pharmacol Exp Ther (1992) 262:729–733.[Abstract/Free Full Text]
70. Wohlfart P., Dedio J., Wirth K., Scholkens B.A., Wiemer G. Different B₁ kinin receptor expression and pharmacology in endothelial cells of different origins and species. J Pharmacol Exp Ther (1997) 280:1109–1116.[Abstract/Free Full Text]
71. Levesque L., Drapeau G., Grose J.H., Rioux F., Marceau F. Vascular mode of action of kinin B₁ receptors and development of a cellular model for the investigation of these receptors. Br J Pharmacol (1993) 109:1254–1262.[Web of Science][Medline]
72. Schneck K.A., Hess J.F., Stonesifer G.Y., Ransom R.W. Bradykinin B₁ receptors in rabbit aorta smooth muscle cells in culture. Eur J Pharmacol (1994) 266:277–282.[CrossRef][Web of Science][Medline]
73. Deblois D., Drapeau G., Petitclerc E., Marceau F. Synergism between the contractile effect of epidermal growth factor and that of des-Arg⁹-bradykinin or of alpha-thrombin in rabbit aortic rings. Br J Pharmacol (1992) 105:959–967.[Web of Science][Medline]
74. Regoli D., Marceau F., Barabe J. De novo formation of vascular receptors for bradykinin. Can J Physiol Pharmacol (1978) 56:674–677.[Web of Science][Medline]
75. Rizzi A., Calo G., Amadesi S., Regoli D. Kinin B₁ and B₂ receptors in pig vessels: characterization of two monoreceptor systems. Naunyn Schmiedeberg's Arch Pharmacol (1997) 356:662–670.[CrossRef][Web of Science][Medline]
76. Abbas F., Clayton J.K., Marshall K.M., Senior J. Characterisation of kinin receptors on the human isolated umbilical artery. J Endocrinol (1998) 156:389–394.[Abstract]
77. Gobeil F., Pheng L.H., Badini I., et al. Receptors for kinins in the human isolated umbilical vein. Br J Pharmacol (1996) 118:289–294.[Web of Science][Medline]
78. Meini S., Quartara L., Rizzi A., et al. MEN 11270, A novel selective constrained peptide antagonist with high affinity at the human B₂ kinin receptor. J Pharmacol Exp Ther (1999) 289:1250–1256.[Abstract/Free Full Text]
79. Bagat K., Develioglu L., Imbs J.L., et al. Vascular kinin B(1) and B(2) receptor-mediated effects in the rat isolated perfused kidney — differential regulations. Br J Pharmacol (1999) 128:1643–1650.[CrossRef][Web of Science][Medline]
80. Bascands J.L., Pecher C., Rouaud S., et al. Evidence for existence of two distinct bradykinin receptors on rat mesangial cells. Am J Physiol (1993) 264:F548–F556.[Web of Science][Medline]
81. DeWitt B.J., Cheng D.Y., Kadowitz P.J. Des-Arg⁹-bradykinin produces tone-dependent kinin B₁ receptor-mediated responses in the pulmonary vascular bed. Circ Res (1994) 75:1064–1072.[Abstract/Free Full Text]
82. Campos A.H., Calixto J.B. Mechanisms involved in the contractile responses of kinins in rat portal vein rings: mediation by B₁ and B₂ receptors. J Pharmacol Exp Ther (1994) 268:902–909.[Abstract/Free Full Text]
83. Drummond G.R., Cocks T.M. Endothelium-dependent relaxations mediated by inducible B₁ and constitutive B₂ kinin receptors in the bovine isolated coronary artery. Br J Pharmacol (1995) 116:2473–2481.[Web of Science][Medline]
84. Pruneau D., Luccarini J.M., Defrene E., Paquet J.L., Belichard P. Characterisation of bradykinin receptors from juvenile pig coronary artery. Eur J Pharmacol (1996) 297:53–60.[CrossRef][Web of Science][Medline]
85. Drummond G.R., Cocks T.M. Endothelium-dependent relaxation to the B₁ kinin receptor agonist des-Arg⁹-bradykinin in human coronary arteries. Br J Pharmacol (1995) 116:3083–3085.[Web of Science][Medline]
86. Deblois D., Marceau F. The ability of des-Arg⁹-bradykinin to relax rabbit isolated mesenteric arteries is acquired during in vitro incubation. Eur J Pharmacol (1987) 142:141–144.[CrossRef][Web of Science][Medline]
87. Pruneau D., Belichard P. Induction of bradykinin B₁ receptor-mediated relaxation in the isolated rabbit carotid artery. Eur J Pharmacol (1993) 239:63–67.[CrossRef][Web of Science][Medline]
88. Santiago J.A., Garrison E.A., Champion H.C., et al. Analysis of responses to kallidin. DABK, and DAK in feline hindlimb vascular bed. Am J Physiol (1995) 269:H2057–2064.[Web of Science][Medline]
89. Churchill L., Ward P.E. Conversion of B₁ kinin receptor-mediated vascular relaxation to contraction. Hypertension (1987) 9:III1–III5.[Medline]
90. Ritter J.M., Doktor H.S., Cragoe E.J. Jr. Actions of bradykinin and related peptides on rabbit coeliac artery rings. Br J Pharmacol (1989) 96:23–28.[Web of Science][Medline]
91. Churchill L., Ward P.E. Relaxation of isolated mesenteric arteries by des-Arg⁹-bradykinin stimulation of B₁ receptors. Eur J Pharmacol (1986) 130:11–18.[CrossRef][Web of Science][Medline]
92. D'Orleans-Juste P., De Nucci G., Regoli D., Vane J. Characterisation of kinin receptors on bovine aortic endothelial cells. Br J Pharmacol (1988) 95:546.
93. Sung C.P., Arleth A.J., Shikano K., Berkowitz B.A. Characterization and function of bradykinin receptors in vascular endothelial cells. J Pharmacol Exp Ther (1988) 247:8–13.[Abstract/Free Full Text]
94. Forstermann U., Hertting G., Neufang B. The importance of endogenous prostaglandins other than prostacyclin, for the modulation of contractility of some rabbit blood vessels. Br J Pharmacol (1984) 81:623–630.[Web of Science][Medline]
95. Simmet T., Hertting G. On the relation between contraction and prostaglandin release in rabbit mesenteric blood vessels. Eur J Pharmacol (1980) 65:325–331.[CrossRef][Web of Science][Medline]
96. Bouchard J.F., Dumont E., Lamontagne D. Evidence that prostaglandins I2, E2, and D2 may activate ATP sensitive potassium channels in the isolated rat heart. Cardiovasc Res (1994) 28:901–905.[Abstract/Free Full Text]
97. Demirel E., Turker R.K. Inhibition of iloprost of the contractile effect of noradrenaline in mesenteric artery rings: evidence for a possible calcium-dependent mechanism. Prostaglandins Leukot Essent Fatty Acids (1991) 42:185–189.[CrossRef][Web of Science][Medline]
98. Galizzi J.P., Bodinier M.C., Chapelain B., et al. Up-regulation of [³H]-des-Arg¹⁰-kallidin binding to the bradykinin B₁ receptor by interleukin-1 beta in isolated smooth muscle cells: correlation with B₁ agonist-induced PGI2 production. Br J Pharmacol (1994) 113:389–394.[Web of Science][Medline]
99. Ribuot C., Godin D., Couture R., Regoli D., Nadeau R. In vivo B₂-receptor-mediated negative chronotropic effect of bradykinin in canine sinus node. Am J Physiol (1993) 265:H876–H879.[Web of Science][Medline]
100. Gouin L., Cardinal R., Adam A., Drapeau G., Nadeau R. Kinin-induced prolongation of action-potential duration in right ventricular muscle from rat: involvement of B₁ and B₂ receptors. J Cardiovasc Pharmacol (1996) 28:337–343.[CrossRef][Web of Science][Medline]
101. Chahine R., Adam A., Yamaguchi N., et al. Protective effects of bradykinin on the ischaemic heart: implication of the B₁ receptor. Br J Pharmacol (1993) 108:318–322.[Web of Science][Medline]
102. Feng J., Yamaguchi N., Foucart S., et al. Transient ischemia inhibits nonexocytotic release of norepinephrine following sustained ischemia in rat heart: is bradykinin involved? Can J Physiol Pharmacol (1997) 75:665–670.[CrossRef][Web of Science][Medline]
103. Foucart S., Grondin L., Couture R., Nadeau R. Modulation of noradrenaline release by B₁ and B₂ kinin receptors during metabolic anoxia in the rat isolated atria. Can J Physiol Pharmacol (1997) 75:639–645.[CrossRef][Web of Science][Medline]
104. Siebeck M., Whalley E.T., Hoffmann H., Weipert J., Fritz H. The hypotensive response to des-Arg⁹-bradykinin increases during E. coli septicemia in the pig. Adv Exp Med Biol (1989) 247B:389–393.
105. Nakhostine N., Ribuot C., Lamontagne D., Nadeau R., Couture R. Mediation by B₁ and B₂ receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs. Br J Pharmacol (1993) 110:71–76.[Web of Science][Medline]
106. Audet R., Rioux F., Drapeau G., Marceau F. Cardiovascular effects of Sar-[D-Phe⁸]des-Arg⁹-bradykinin, a metabolically protected agonist of B₁ receptor for kinins, in the anesthetized rabbit pretreated with a sublethal dose of bacterial lipopolysaccharide. J Pharmacol Exp Ther (1997) 280:6–15.[Abstract/Free Full Text]
107. Siebeck M., Schorr M., Spannagl E., et al. B₁ kinin receptor activity in pigs is associated with pre-existing infection. Immunopharmacology (1998) 40:49–55.[CrossRef][Web of Science][Medline]
108. Caligiorne S.M., Santos R.A., Campagnole-Santos M.J. Cardiovascular effects produced by bradykinin microinjection into the nucleus tractus solitarii of anesthetized rats. Brain Res (1996) 720:183–190.[CrossRef][Web of Science][Medline]
109. Alvarez A.L., Delorenzi A., Santajuliana D., et al. Central bradykininergic system in normotensive and hypertensive rats. Clin Sci (Colch) (1992) 82:513–519.[Medline]
110. Lagneux C., Joyeux M., Bricca G., Demenge P., Ribuot C. Hypertension in transgenic (mREN2)27 rats is not associated with the presence of B₁ receptors. Fundam Clin Pharmacol (2000) 14:119–123.[Web of Science][Medline]
111. Emanueli C., Chao J., Regoli D., et al. The bradykinin B₁ receptor and the central regulation of blood pressure in spontaneously hypertensive rats. Br J Pharmacol (1999) 126:1769–1776.[CrossRef][Web of Science][Medline]
112. Martins D.T., Fior D.R., Nakaie C.R., Lindsey C.J. Kinin receptors of the central nervous system of spontaneously hypertensive rats related to the pressor response to bradykinin. Br J Pharmacol (1991) 103:1851–1856.[Web of Science][Medline]
113. Vianna R.M., Calixto J.B. Characterization of the receptor and the mechanisms underlying the inflammatory response induced by des-Arg⁹-BK in mouse pleurisy. Br J Pharmacol (1998) 123:281–291.[CrossRef][Web of Science][Medline]
114. Perron M.S., Gobeil F.J., Pelletier S., Regoli D., Sirois P. Involvement of bradykinin B₁ and B₂ receptors in pulmonary leukocyte accumulation induced by Sephadex beads in guinea pigs. Eur J Pharmacol (1999) 376:83–89.[CrossRef][Web of Science][Medline]
115. Pesquero JB, Araujo RC, Heppenstall PA et al. Hypoalgesia and altered inflammatory responses in mice lacking kinin B₁ receptors. Proc Natl Acad Sci USA 2000: in press.
116. Alfie M.E., Yang X.P., Hess F., Carretero O.A. Salt-sensitive hypertension in bradykinin B₂ receptor knockout mice. Biochem Biophys Res Commun (1996) 224:625–630.[CrossRef][Web of Science][Medline]
117. Alfie M.E., Sigmon D.H., Pomposiello S.I., Carretero O.A. Effect of high salt intake in mutant mice lacking bradykinin-B₂ receptors. Hypertension (1997) 29:483–487.[Abstract/Free Full Text]
118. Ahluwalia A., Flower R.J. Investigations into the mechanism of vasoconstrictor action of the topical steroid betamethasone-17-valerate in the rat. Br J Pharmacol (1993) 108:544–548.[Web of Science][Medline]
119. Cruwys S.C., Garrett N.E., Perkins M.N., Blake D.R., Kidd B.L. The role of bradykinin B₁ receptors in the maintenance of intra-articular plasma extravasation in chronic antigen-induced arthritis. Br J Pharmacol (1994) 113:940–944.[Web of Science][Medline]
120. Ahluwalia A., Perretti M. Involvement of bradykinin B₁ receptors in the polymorphonuclear leukocyte accumulation induced by IL-1 beta in vivo in the mouse. J Immunol (1996) 156:269–274.[Abstract]
121. Asako H., Kurose I., Wolf R., et al. Role of H1 receptors and P-selectin in histamine-induced leukocyte rolling and adhesion in postcapillary venules. J Clin Invest (1994) 93:1508–1515.[Web of Science][Medline]
122. Carl V.S., Moore E.E., Moore F.A., Whalley E.T. Involvement of bradykinin B₁ and B₂ receptors in human PMN elastase release and increase in endothelial cell monolayer permeability. Immunopharmacology (1996) 33:325–329.[CrossRef][Web of Science][Medline]
123. McFadden R.G., Vickers K.E. Bradykinin augments the in vitro migration of nonsensitized lymphocytes. Clin Invest Med (1989) 12:247–253.[Web of Science][Medline]
124. Prat A., Weinrib L., Becher B., et al. Bradykinin B₁ receptor expression and function on T lymphocytes in active multiple sclerosis. Neurology (1999) 53:2087–2092.[Abstract/Free Full Text]
125. Shigematsu S., Ishida S., Gute D.C., Korthuis R.J. Concentration-dependent effects of bradykinin on leukocyte recruitment and venular hemodynamics in rat mesentery. Am J Physiol (1999) 277:H152–H160.[Web of Science][Medline]
126. Pixley P.A., Colman R.W. The kinin system. Famer S.G., ed. (1997) San Diego: Academic Press. 173–186.
127. Danner R.L., Elin R.J., Hosseini J.M., et al. Endotoxemia in human septic shock. Chest (1991) 99:169–175.[CrossRef][Web of Science][Medline]
128. McCuskey R.S., Urbaschek R., Urbaschek B. The microcirculation during endotoxemia. Cardiovasc Res (1996) 32:752–763.[Abstract/Free Full Text]
129. Cunnion R.E., Schaer G.L., Parker M.M., Natanson C., Parrillo J.E. The coronary circulation in human septic shock. Circulation (1986) 73:637–644.[Abstract/Free Full Text]
130. Vallance P., Charles I.G. Nitric oxide in sepsis: of mice and men. Sepsis (2000) 1:93–100.[CrossRef]
131. Keller R.S., Jones J.J., Kim K.F., et al. Endotoxin-induced myocardial dysfunction: is there a role for nitric oxide? Shock (1995) 4:338–344.[Web of Science][Medline]
132. Paya D., Stoclet J.C. Involvement of bradykinin and nitric oxide in the early hemodynamic effects of lipopolysaccharide in rats. Shock (1995) 3:376–379.[Web of Science][Medline]
133. Marceau F., Larrivee J.F., Saint-Jacques E., Bachvarov D.R. The kinin B₁ receptor: an inducible G protein coupled receptor. Can J Physiol Pharmacol (1997) 75:725–730.[CrossRef][Web of Science][Medline]
134. Kontos M.A., Magee J.H., Shapiro W. General and regional circulation effects of synthetic bradykinin in man. Circ Res (1964) 14:352.
135. Nies A.S., Forsyth R.P., Williams H.E., Melmon K.L. Contribution of kinins to endotoxin shock in unanesthetized Rhesus monkeys. Circ Res (1968) 22:155–164.[Abstract/Free Full Text]
136. Wilson D.D., de Garavilla L., Kuhn W., et al. D-Arg-[Hyp³-D-Phe⁷]-bradykinin, a bradykinin antagonist, reduces mortality in a rat model of endotoxic shock. Circ Shock (1989) 27:93–101.[Web of Science][Medline]
137. Mazenot C., Ribuot C., Demenge P., Godin-Ribuot D. Monophosphoryl lipid A, a derivative of bacterial lipopolysaccharide, fails to induce B₁-receptor-dependent responses to (des-Arg⁹)-bradykinin in the rabbit in vivo. Immunopharmacology (1999) 41:165–168.[CrossRef][Web of Science][Medline]
138. DeLa C.R., Suffredini A.F., Page J.D., et al. Activation of the kallikrein–kinin system after endotoxin administration to normal human volunteers. Blood (1993) 81:3313–3317.[Abstract/Free Full Text]
139. Hirsch E.F., Nakajima T., Oshima G., Erdos E.G., Herman C.M. Kinin system responses in sepsis after trauma in man. J Surg Res (1974) 17:147–153.[CrossRef][Web of Science][Medline]
140. O'Donnell T.F.J., Clowes G.H.J., Talamo R.C., Colman R.W. Kinin activation in the blood of patients with sepsis. Surg Gynecol Obstet (1976) 143:539–545.[Web of Science][Medline]
141. Robinson J.A., Klondnycky M.L., Loeb H.S., Racic M.R., Gunnar R.M. Endotoxin, prekallikrein, complement and systemic vascular resistance. Am J Med (1975) 59:61–67.[CrossRef][Web of Science][Medline]
142. Kalter E.S., Daha M.R., ten Cate J.W., Verhoef J., Bouma B.N. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis (1985) 151:1019–1027.[Web of Science][Medline]
143. Whalley E.T., Solomon J.A., Modafferi D.M., Bonham K.A., Cheronis J.C. CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock. Agents Actions Suppl (1992) 38:413–420.[Medline]
144. Ueno A., Ishida H., Oh-ishi S. Comparative study of endotoxin-induced hypotension in kininogen-deficient rats with that in normal rats. Br J Pharmacol (1995) 114:1250–1256.[Web of Science][Medline]
145. Siebeck M., Spannagl E., Schorr M., et al. Effect of combined B₁ and B₂ kinin receptor blockade in porcine endotoxin shock. Immunopharmacology (1996) 33:81–84.[CrossRef][Web of Science][Medline]
146. Feletou M., Lonchampt M., Robineau P., et al. Effects of the bradykinin B₂ receptor antagonist S 16118 (p-guanidobenzoyl-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin) in different in vivo animal models of inflammation. J Pharmacol Exp Ther (1995) 273:1078–1084.[Abstract/Free Full Text]
147. Berg T., Schlichting E., Ishida H., Carretero O.A. Kinin antagonist does not protect against the hypotensive response to endotoxin, anaphylaxis or acute pancreatitis. J Pharmacol Exp Ther (1989) 251:731–734.[Abstract/Free Full Text]
148. Otterbein L., Lowe V.C., Kyle D.J., Noronha-Blob L. Additive effects of a bradykinin antagonist, NPC 17761, and a leumedin, NPC 15669, on survival in animal models of sepsis. Agents Actions (1993) 39:C125–C127.[CrossRef][Web of Science][Medline]
149. Cheronis J.C., Whalley E.T., Nguyen K.T., et al. A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J Med Chem (1992) 35:1563–1572.[CrossRef][Web of Science][Medline]
150. Whalley E.T., Loy S.D., Modafferi D.M., et al. A novel potent bis-succinimido hexane peptide heterodimer antagonist CP-0364 of bradykinin BK-1 and BK-2 receptors in vitro and in vivo studies. Br J Pharmacol (1992) 107:257. (Abstract).
151. Regoli D., Rhaleb N.E., Drapeau G., et al. Basic pharmacology of kinins: pharmacologic receptors and other mechanisms. Adv Exp Med Biol (1989) 247A:399–407.
152. Fein A.M., Bernard G.R., Criner G.J., et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). J Am Med Assoc (1997) 277:482–487.[Abstract/Free Full Text]
153. Mazenot C., Demenge P., Godin-Ribuot D. Myocardial ischaemia induces B₁ receptors in the rabbit. Mediators of Inflammation (1999) 8:S158. (Abstract).
154. Bouchard J.F., Chouinard J., Lamontagne D. Role of kinins in the endothelial protective effect of ischaemic preconditioning. Br J Pharmacol (1998) 123:413–420.[CrossRef][Web of Science][Medline]
155. Nolly H., Carbini L.A., Scicli G., Carretero O.A., Scicli A.G. A local kallikrein–kinin system is present in rat hearts. Hypertension (1994) 23:919–923.[Abstract/Free Full Text]
156. Duncan A.M., Burrell L.M., Kladis A., Campbell D.J. Angiotensin and bradykinin peptides in rats with myocardial infarction. J Card Fail (1997) 3:41–52.[CrossRef][Medline]
157. Duncan A.M., Burrell L.M., Kladis A., Campbell D.J. Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. J Cardiovasc Pharmacol (1996) 28:746–754.[CrossRef][Web of Science][Medline]
158. Shigematsu S., Ishida S., Gute D.C., Korthuis R.J. Bradykinin prevents postischemic leukocyte adhesion and emigration and attenuates microvascular barrier disruption. Am J Physiol (1999) 277:H161–H171.[Web of Science][Medline]
159. Hartman J.C., Wall T.M., Hullinger T.G., Shebuski R.J. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol (1993) 21:996–1003.[Web of Science][Medline]
160. Linz W., Wiemer G., Scholkens B.A. Role of kinins in the pathophysiology of myocardial ischemia. Diabetes (1996) 45(Suppl_1):S51–S58.[CrossRef][Web of Science][Medline]
161. Vegh A., Szekeres L., Parratt J.R. Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetized dogs. Br J Pharmacol (1991) 104:294–295.[Web of Science][Medline]
162. Hoffmann T.F., Waldner H., Messmer K. The bradykinin antagonist CP-0597 can limit the progression of postischemic pancreatitis. Immunopharmacology (1996) 33:243–246.[CrossRef][Web of Science][Medline]
163. Lehmberg J., Beck J., Baethmann A., et al. Inhibition of leukocyte–endothelium interactions in the brain in global ischemia by the bradykinin B₁-receptor-antagonist B 9430. In: Brain'99 XIXth international symposium on cerebral blood flow and metabolism, Copenhagen, Denmark, June 13–17 (1999) 573. Abstract.
164. Relton J.K., Rothwell N.J., Whalley E.T. Blockade of the bradykinin B₁ receptor reverses the neuroprotective effect of B₂ receptor antagonism after focal cerebral ischaemia in the rat. Br J Pharmacol (1999) 120:76. (Abstract).
165. Yang X.P., Liu Y.H., Scicli G.M., Webb C.R., Carretero O.A. Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B₂ kinin receptor knockout mice and kininogen-deficient rats. Hypertension (1997) 30:735–740.[Abstract/Free Full Text]
166. Vegh A., Papp J.G., Parratt J. Attenuation of the antiarrhythmic effects of ischaemic preconditioning by blockade of bradykinin B₂ receptors. Br J Pharmacol (1994) 113:1167–1172.[Web of Science][Medline]
167. Wall T.M., Sheehy R., Hartman J.C. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther (1994) 270:681–689.[Abstract/Free Full Text]
168. Brew E.C., Mitchell M.B., Rehring T.F., et al. Role of bradykinin in cardiac functional protection after global ischemia–reperfusion in rat heart. Am J Physiol (1995) 269:H1370–H1378.[Web of Science][Medline]
169. Pruneau D., Luccarini J.M., Robert C., Belichard P. Induction of kinin B₁ receptor-dependent vasoconstriction following balloon catheter injury to the rabbit carotid artery. Br J Pharmacol (1994) 111:1029–1034.[Web of Science][Medline]
170. Dixon B.S., Dennis M.J. Regulation of mitogenesis by kinins in arterial smooth muscle cells. Am J Physiol (1997) 273:C7–20.[Web of Science][Medline]
171. Lommi J., Pulkki K., Koskinen P., et al. Haemodynamic, neuroendocrine and metabolic correlates of circulating cytokine concentrations in congestive heart failure. Eur Heart J (1997) 18:1620–1625.[Abstract/Free Full Text]
172. Zychma M.J., Gumprecht J., Zukowska-Szczechowska E., Grzeszczak W. Polymorphisms in the genes encoding for human kinin receptors and the risk of end-stage renal failure: results of transmission/disequilibrium test. J Am Soc Nephrol (1999) 10:2120–2124.[Abstract/Free Full Text]
173. Bachvarov D.R., Landry M., Pelletier I., et al. Characterization of two polymorphic sites in the human kinin B₁ receptor gene: altered frequency of an allele in patients with a history of end-stage renal failure. J Am Soc Nephrol (1998) 9:598–604.[Abstract]

CiteULike    Connotea    Del.icio.us    What's this?

This article has been cited by other articles:

				J. Duchene, C. Cayla, S. Vessillier, R. Scotland, K. Yamashiro, F. Lecomte, I. Syed, P. Vo, A. Marrelli, C. Pitzalis, et al. Laminar Shear Stress Regulates Endothelial Kinin B1 Receptor Expression and Function: Potential Implication in Atherogenesis Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1757 - 1763. [Abstract] [Full Text] [PDF]

				L. G. Coffman, J. C. Brown, D. A. Johnson, N. Parthasarathy, R. B. D'Agostino Jr., M. O. Lively, X. Hua, S. L. Tilley, W. Muller-Esterl, M. C. Willingham, et al. Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin Am J Physiol Lung Cell Mol Physiol, March 1, 2008; 294(3): L505 - L515. [Abstract] [Full Text] [PDF]

				J. Duchene, F. Lecomte, S. Ahmed, C. Cayla, J. Pesquero, M. Bader, M. Perretti, and A. Ahluwalia A Novel Inflammatory Pathway Involved in Leukocyte Recruitment: Role for the Kinin B1 Receptor and the Chemokine CXCL5 J. Immunol., October 1, 2007; 179(7): 4849 - 4856. [Abstract] [Full Text] [PDF]

				S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen Angiotensin-Converting Enzyme and Vascular Remodeling Circ. Res., August 31, 2007; 101(5): 441 - 454. [Abstract] [Full Text] [PDF]

				C. Cayla, M. Todiras, R. Iliescu, V. V. Saul, V. Gross, B. Pilz, G. Chai, V. F. Merino, J. B. Pesquero, O. C. Baltatu, et al. Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension FASEB J, June 1, 2007; 21(8): 1689 - 1698. [Abstract] [Full Text] [PDF]

				U. Danilczyk and J. M. Penninger Angiotensin-Converting Enzyme II in the Heart and the Kidney Circ. Res., March 3, 2006; 98(4): 463 - 471. [Abstract] [Full Text] [PDF]

				S. Stanisavljevic, T. Ignjatovic, P. A. Deddish, V. Brovkovych, K. Zhang, E. G. Erdos, and R. A. Skidgel Angiotensin I-Converting Enzyme Inhibitors Block Protein Kinase C{epsilon} by Activating Bradykinin B1 Receptors in Human Endothelial Cells J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1153 - 1158. [Abstract] [Full Text] [PDF]

				T. Rhen and J. A. Cidlowski Estrogens and Glucocorticoids Have Opposing Effects on the Amount and Latent Activity of Complement Proteins in the Rat Uterus Biol Reprod, February 1, 2006; 74(2): 265 - 274. [Abstract] [Full Text] [PDF]

				E. Kintsurashvili, A. Duka, I. Ignjacev, G. Pattakos, I. Gavras, and H. Gavras Age-related changes of bradykinin B1 and B2 receptors in rat heart Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H202 - H205. [Abstract] [Full Text] [PDF]

				N. L.M. Cruden, G. H. Tse, K. A.A. Fox, C. A. Ludlam, I. Megson, and D. E. Newby B1 Kinin Receptor Does Not Contribute to Vascular Tone or Tissue Plasminogen Activator Release in the Peripheral Circulation of Patients With Heart Failure Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 772 - 777. [Abstract] [Full Text] [PDF]

				T. Ignjatovic, S. Stanisavljevic, V. Brovkovych, R. A. Skidgel, and E. G. Erdos Kinin B1 Receptors Stimulate Nitric Oxide Production in Endothelial Cells: Signaling Pathways Activated by Angiotensin I-Converting Enzyme Inhibitors and Peptide Ligands Mol. Pharmacol., November 1, 2004; 66(5): 1310 - 1316. [Abstract] [Full Text] [PDF]

				N. L.M. Cruden, F. N. Witherow, D. J. Webb, K. A.A. Fox, and D. E. Newby Bradykinin Contributes to the Systemic Hemodynamic Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1043 - 1048. [Abstract] [Full Text] [PDF]

				R. Medeiros, D. A. Cabrini, J. Ferreira, E. S. Fernandes, M. A.S. Mori, J. B. Pesquero, M. Bader, M. C.W. Avellar, M. M. Campos, and J. B. Calixto Bradykinin B1 Receptor Expression Induced by Tissue Damage in the Rat Portal Vein: A Critical Role for Mitogen-Activated Protein Kinase and Nuclear Factor-{kappa}B Signaling Pathways Circ. Res., May 28, 2004; 94(10): 1375 - 1382. [Abstract] [Full Text] [PDF]

				Y.-H. Liu, X.-P. Yang, E. G. Shesely, S. S. Sankey, and O. A. Carretero Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure J. Am. Coll. Cardiol., April 21, 2004; 43(8): 1473 - 1480. [Abstract] [Full Text] [PDF]

				C. Tschope, F. Spillmann, C. Altmann, M. Koch, D. Westermann, N. Dhayat, S. Dhayat, J.-L. Bascands, L. Gera, S. Hoffmann, et al. The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction Cardiovasc Res, February 15, 2004; 61(3): 559 - 569. [Abstract] [Full Text] [PDF]

				A. P. V. Dantas, J. Igarashi, and T. Michel Sphingosine 1-phosphate and control of vascular tone Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2045 - H2052. [Abstract] [Full Text] [PDF]

				A. Ni, H. Yin, J. Agata, Z. Yang, L. Chao, and J. Chao Overexpression of Kinin B1 Receptors Induces Hypertensive Response to Des-Arg9-bradykinin and Susceptibility to Inflammation J. Biol. Chem., January 3, 2003; 278(1): 219 - 225. [Abstract] [Full Text] [PDF]

				D. A. Bradbury, R. Newton, Y.-M. Zhu, J. Stocks, L. Corbett, E. D. Holland, L. H. Pang, and A. J. Knox Effect of bradykinin, TGF-beta 1, IL-1beta , and hypoxia on COX-2 expression in pulmonary artery smooth muscle cells Am J Physiol Lung Cell Mol Physiol, October 1, 2002; 283(4): L717 - L725. [Abstract] [Full Text] [PDF]

				T. Sabourin, G. Morissette, J. Bouthillier, L. Levesque, and F. Marceau Expression of kinin B1 receptor in fresh or cultured rabbit aortic smooth muscle: role of NF-kappa B Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H227 - H237. [Abstract] [Full Text] [PDF]

				T. Ignjatovic, F. Tan, V. Brovkovych, R. A. Skidgel, and E. G. Erdos Novel Mode of Action of Angiotensin I Converting Enzyme Inhibitors. DIRECT ACTIVATION OF BRADYKININ B1 RECEPTOR J. Biol. Chem., May 3, 2002; 277(19): 16847 - 16852. [Abstract] [Full Text] [PDF]

				M. E. Marin-Castano, J. P. Schanstra, E. Neau, F. Praddaude, C. Pecher, J.-L. Ader, J.-P. Girolami, and J.-L. Bascands Induction of Functional Bradykinin B1-Receptors in Normotensive Rats and Mice Under Chronic Angiotensin-Converting Enzyme Inhibitor Treatment Circulation, February 5, 2002; 105(5): 627 - 632. [Abstract] [Full Text] [PDF]

				I. Duka, S. Shenouda, C. Johns, E. Kintsurashvili, I. Gavras, and H. Gavras Role of the B2 Receptor of Bradykinin in Insulin Sensitivity Hypertension, December 1, 2001; 38(6): 1355 - 1360. [Abstract] [Full Text] [PDF]

				E. Kintsurashvili, I. Duka, I. Gavras, C. Johns, D. Farmakiotis, and H. Gavras Effects of ANG II on bradykinin receptor gene expression in cardiomyocytes and vascular smooth muscle cells Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1778 - H1783. [Abstract] [Full Text] [PDF]

This Article Abstract FREE Full Text (PDF) E-letters: Submit a response Alert me when this article is cited Alert me when E-letters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (51) Request Permissions Disclaimer Google Scholar Articles by McLean, P. G. Articles by Ahluwalia, A. Search for Related Content PubMed Articles by McLean, P. G. Articles by Ahluwalia, A. Social Bookmarking          What's this?

Online ISSN 1755-3245 - Print ISSN 0008-6363

Copyright © 2009 European Society of Cardiology

Oxford Journals Oxford University Press

• Site Map
• Privacy Policy
• Frequently Asked Questions

Other Oxford University Press sites: Oxford University Press Oxford Journals China Oxford Journals Japan American National Biography Booksellers' Information Service Children's Fiction and Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights and Permissions Science School Books Social Sciences Very Short Introductions World's Classics